… of the systematic review could not be applied to the scales that are related to peripheral
neuropathy caused by other comorbidities, such as diabetes, that might conflate assessment. …

… Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of …
assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN …

… the prevalence and assessment of chemotherapy-induced peripheral neuropathy (CIPN).
This … and its characteristics in patients receiving taxane- and platinum-based chemotherapy. …

… The focus of this study was to assess the feasibility and clinical implementation of a
standardized assessment for chemotherapy-induced peripheral neuropathy (CIPN) by registered …

… Peripheral neuropathies are among the most frequently occurring and distressing adverse
effects of chemotherapy. … Severe peripheral neuropathies may result in dose reductions, a …

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often …
assessment tools that measure or assess CIPN in adult patients receiving chemotherapy. …

… concurrent interference with the antitumor activity of chemotherapy by these approaches. …
to neurotoxic chemotherapeutic agents, and the clinical challenges in the assessment and …

… assessment is essential for the management of chemotherapy-induced peripheral neuropathy
(… We developed a comprehensive assessment scale for CIPN in cancer survivors, named …

… properties (reliability, validity, and responsiveness) and (2) to provide rationale for selection
of tests when assessing CIPN in patients receiving peripheral neurotoxic chemotherapy. …

… Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most important adverse
events that renders prolonged chemotherapy difficult. To assess the features of CIPN, we …